John Hyngstrom

John Hyngstrom, MD

Languages spoken: English

Academic Information

Departments Adjunct - Surgery

Divisions: Surgical Oncology

Board Certification

  • American Board of Surgery

Dr. Hyngstrom is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the department of Surgery at the University of Utah. His medical practice is in general surgical oncology with a focus on melanoma and sarcoma, treating patients at the Huntsman Cancer Institute. His research interests include immunotherapy clinical trial development and survivorship issues in cancer patients. He currently serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on improving care for patients with advanced melanoma and other solid tumors. He is physician lead of the melanoma Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI. He also serves as the Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.

Dr. Hyngstrom earned his Bachelor of Arts degree from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from the University of Chicago Pritzker School of Medicine and completed his general surgery residency at the University of Chicago Medical Center. During his residency, he completed a two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. After finishing his general surgery training, Dr. Hyngstrom completed a complex general surgical oncology fellowship at the University of Texas MD Anderson Cancer Center. Since 2012, he has worked as a faculty surgeon at the University of Utah Huntsman Cancer Institute, and as a contracted surgeon at Intermountain Medical Center. He also serves part-time at the George Wahlen VA Hospital in Salt Lake City, Utah.

Education History

Undergraduate Washington University
 BA
Professional Medical The University of Chicago Pritzker School of Medicine
 MD
Residency University of Chicago Medical Center, the Pritzker School of Medicine
 Resident
Fellowship National Cancer Institute, Surgery Branch
 Fellow
Fellowship The University of Texas MD Anderson Cancer Center
 Fellow

Selected Publications

Journal Article

  1. Walker HR, Evans E, Nirula R, Hyngstrom J, Matsen C, Nelson E, Pickron B, Zurbuchen E, Morrow E (2021). "I need to have a fulfilling job": A qualitative study of surgeon well-being and professional fulfillment. American journal of surgery, 223(1), 6-11. (Read full article)
  2. Bleicher J, Asare EA, Flores S, Bowles TL, Bowen GM, Hyngstrom J (2021). Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study. American journal of surgery, 221(4), 844-849. (Read full article)
  3. Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom J (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta oncologica (Stockholm, Sweden), 59(4), 434-437. (Read full article)
  4. Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier J (2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma research, 23(4), 290--7.
  5. Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles T (2020). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Melanoma research, 30(2), 173-178. (Read full article)
  6. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma research, 27(5), 477-484. (Read full article)
  7. Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples G (2021). Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma research, 31(4), 378-388. (Read full article)
  8. Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright L (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). Journal of the American Academy of Dermatology, 79(2), 238-244. (Read full article)
  9. Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas M (2014). Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. Journal of surgical oncology, 109(7), 652-8. (Read full article)
  10. Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, Bowles TL, Hyngstrom J (2020). Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. Journal of surgical oncology, 122(8), 1770-1777. (Read full article)
  11. Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang G (2012). Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Annals of surgical oncology, 19(9), 2814-21. (Read full article)
  12. Park SH, Kwon OS, Park SY, Weavil JC, Hydren JR, Reese V, Andtbacka RHI, Hyngstrom JR, Richardson R (2020). Vasodilatory and vascular mitochondrial respiratory function with advancing age: evidence of a free radically mediated link in the human vasculature. American journal of physiology. Regulatory, integrative and comparative physiology, 318(4), R701-R711. (Read full article)
  13. Bleicher J, Cohan JN, Huang LC, Peche W, Pickron TB, Scaife CL, Bowles TL, Hyngstrom JR, Asare E (2021). Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature. World journal of gastroenterology, 27(3), 267-280. (Read full article)
  14. Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom J (2021). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. Journal of oncology pharmacy practice, 27(3), 555-559. (Read full article)
  15. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong H (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399. (Read full article)
  16. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom J (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer medicine, 8(18), 7637-7643. (Read full article)
  17. Chick RC, Faries MB, Hale DF, Kemp Bohan PM, Hickerson AT, Vreeland TJ, Myers JW 3rd, Cindass JL, Brown TA 2nd, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Clifton GT, Park H, Sloan AJ, Wagner T, Peoples G (2021). Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Cancer medicine, 10(13), 4302-4311. (Read full article)
  18. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter S (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA dermatology, 156(9), 1004-1011. (Read full article)
  19. Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, Anderson A, Chan E, Faries M, Ross M (2021). Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nature medicine, 27(10), 1789-1796. (Read full article)
  20. Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin J (2021). Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. Journal for immunotherapy of cancer, 9(10), (Read full article)
  21. Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier J (2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma research, 23(4), 290-7. (Read full article)
  22. Multicenter Selective Lymphadenectomy Trials Study Group., Crystal JS, Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries M (2022). Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA surgery, 157, 835-842. (Read full article)
  23. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas (2022). Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of clinical oncology, JCO2200343. (Read full article)
  24. Adams AM, Carpenter EL, Clifton GT, Vreeland TJ, Chick RC, O'Shea AE, McCarthy PM, Kemp Bohan PM, Hickerson AT, Valdera FA, Tiwari A, Hale DF, Hyngstrom JR, Berger AC, Jakub JW, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries MB, Peoples G (2022). Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial. Cancer immunology, immunotherapy, (Read full article)
  25. Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, Jackson JA, Wada DA, Rathore R, Budde G, Grandemange A, Hyngstrom J (2023). Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma research, 33(3), 184-191. (Read full article)
  26. Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas (2023). Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine, 388(9), 813-823. (Read full article)
  27. Kwon OS, Noh SG, Park SH, Andtbacka RHI, Hyngstrom JR, Richardson R (2023). Ageing and endothelium-mediated vascular dysfunction: the role of the NADPH oxidases. The Journal of physiology, 601(3), 451-467. (Read full article)
  28. Curti BD, Richards J, Hyngstrom JR, Daniels GA, Faries M, Feun L, Margolin KA, Hallmeyer S, Grose M, Zhang Y, Li A, Andtbacka RH (2022). Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. Journal for immunotherapy of cancer, 10(12), (Read full article)
  29. Dummer R, Gyorki DE, Hyngstrom JR, Ning M, Lawrence T, Ross M (2023). Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. JAMA oncology, 9(10), 1457-1459. (Read full article)
  30. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Frontiers in immunology, 14, 1229823. (Read full article)
  31. Carpenter EL, Van Decar S, Adams AM, O'Shea AE, McCarthy P, Chick RC, Clifton GT, Vreeland T, Valdera FA, Tiwari A, Hale D, Kemp Bohan P, Hickerson A, Smolinsky T, Thomas K, Cindass J, Hyngstrom J, Berger AC, Jakub J, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries M, Peoples G (2023). Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis. Journal for immunotherapy of cancer, 11(8), (Read full article)
  32. Fastner S, Creveling P, Shen N, Horns JJ, Bowles TL, Hyngstrom J, Asare E (2024). Single-Photon Emission Computed Tomography/Computed Tomography Utilization for Extremity Melanomas at a High-Volume Center. The Journal of surgical research, 296, 196-202. (Read full article)
  33. Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan (2024). Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma. Journal for immunotherapy of cancer, 12(1), (Read full article)

Review

  1. Fastner S, Hieken TJ, McWilliams RR, Hyngstrom (2023). Anorectal melanoma. Journal of surgical oncology, 128(4), 635-644. (Read full article)

Case Report

  1. Shah A, Hyngstrom J, Florell SR, Grossman (2019). Use of the Pigmented Lesion Assay to rapidly screen a patient with numerous clinically atypical pigmented lesions. JAAD case reports, 5(12), 1048-1050. (Read full article)

Letter

  1. Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman (2014). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. Journal of the American Academy of Dermatology, 71(4), 835-8. (Read full article)
  2. Bilimoria KY, Russell MC, Hyngstrom (2017). Melanoma Sentinel-Node Metastasis. The New England journal of medicine, 377(9), 891. (Read full article)
  3. Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries M (2023). Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. Annals of surgical oncology, 30(7), 4359-4360. (Read full article)